Financhill
Sell
43

XNCR Quote, Financials, Valuation and Earnings

Last price:
$9.10
Seasonality move :
6.25%
Day range:
$9.00 - $9.46
52-week range:
$7.16 - $27.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.92x
P/B ratio:
1.02x
Volume:
421.6K
Avg. volume:
1M
1-year change:
-56.87%
Market cap:
$654.1M
Revenue:
$110.5M
EPS (TTM):
-$3.09

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
XNCR
Xencor
$24.8M -$0.58 -5.5% -34.49% $28.20
AMGN
Amgen
$8B $4.26 5.67% 279.07% $314.70
CPRX
Catalyst Pharmaceuticals
$131.1M $0.53 14.43% 64.07% $34.29
NKTR
Nektar Therapeutics
$15.4M -$2.82 -54.72% -25.7% $4.92
RARE
Ultragenyx Pharmaceutical
$144.5M -$1.64 9.48% -13.24% $89.84
REGN
Regeneron Pharmaceuticals
$3.2B $8.48 -7.35% -30.58% $727.21
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
XNCR
Xencor
$9.19 $28.20 $654.1M -- $0.00 0% 4.92x
AMGN
Amgen
$295.22 $314.70 $158.7B 26.94x $2.38 3.14% 4.68x
CPRX
Catalyst Pharmaceuticals
$23.53 $34.29 $2.9B 14.99x $0.00 0% 5.54x
NKTR
Nektar Therapeutics
$8.59 $4.92 $106.6M -- $0.00 0% 1.38x
RARE
Ultragenyx Pharmaceutical
$37.49 $89.84 $3.5B -- $0.00 0% 5.94x
REGN
Regeneron Pharmaceuticals
$529.24 $727.21 $57.1B 13.47x $0.88 0.33% 4.29x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
XNCR
Xencor
-- 1.071 -- 5.74x
AMGN
Amgen
90.24% -0.159 34.26% 0.74x
CPRX
Catalyst Pharmaceuticals
-- 0.007 -- 5.85x
NKTR
Nektar Therapeutics
-- 0.622 -- 3.11x
RARE
Ultragenyx Pharmaceutical
-- 0.723 -- 2.03x
REGN
Regeneron Pharmaceuticals
6.33% -0.086 2.89% 3.90x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
XNCR
Xencor
-- -$43.2M -30.26% -32.34% -120.98% -$17.7M
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
CPRX
Catalyst Pharmaceuticals
$123.5M $63.4M 29.43% 29.43% 44.81% $60M
NKTR
Nektar Therapeutics
$10.5M -$44.4M -201.73% -201.73% -395.75% -$49.1M
RARE
Ultragenyx Pharmaceutical
$110.6M -$142.9M -205.06% -205.06% -97.23% -$182.8M
REGN
Regeneron Pharmaceuticals
$2.6B $591.7M 14.69% 15.7% 30.17% $773.6M

Xencor vs. Competitors

  • Which has Higher Returns XNCR or AMGN?

    Amgen has a net margin of -147.92% compared to Xencor's net margin of 21.23%. Xencor's return on equity of -32.34% beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About XNCR or AMGN?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Amgen has an analysts' consensus of $314.70 which suggests that it could grow by 6.6%. Given that Xencor has higher upside potential than Amgen, analysts believe Xencor is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    AMGN
    Amgen
    10 15 2
  • Is XNCR or AMGN More Risky?

    Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Amgen has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.15%.

  • Which is a Better Dividend Stock XNCR or AMGN?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.14% to investors and pays a quarterly dividend of $2.38 per share. Xencor pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or AMGN?

    Xencor quarterly revenues are $32.7M, which are smaller than Amgen quarterly revenues of $8.1B. Xencor's net income of -$48.4M is lower than Amgen's net income of $1.7B. Notably, Xencor's price-to-earnings ratio is -- while Amgen's PE ratio is 26.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 4.68x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.92x -- $32.7M -$48.4M
    AMGN
    Amgen
    4.68x 26.94x $8.1B $1.7B
  • Which has Higher Returns XNCR or CPRX?

    Catalyst Pharmaceuticals has a net margin of -147.92% compared to Xencor's net margin of 40.12%. Xencor's return on equity of -32.34% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    CPRX
    Catalyst Pharmaceuticals
    87.34% $0.45 $794.3M
  • What do Analysts Say About XNCR or CPRX?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.29 which suggests that it could grow by 45.71%. Given that Xencor has higher upside potential than Catalyst Pharmaceuticals, analysts believe Xencor is more attractive than Catalyst Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    CPRX
    Catalyst Pharmaceuticals
    6 0 0
  • Is XNCR or CPRX More Risky?

    Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.922%.

  • Which is a Better Dividend Stock XNCR or CPRX?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or CPRX?

    Xencor quarterly revenues are $32.7M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Xencor's net income of -$48.4M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Xencor's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 14.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 5.54x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.92x -- $32.7M -$48.4M
    CPRX
    Catalyst Pharmaceuticals
    5.54x 14.99x $141.4M $56.7M
  • Which has Higher Returns XNCR or NKTR?

    Nektar Therapeutics has a net margin of -147.92% compared to Xencor's net margin of -486.44%. Xencor's return on equity of -32.34% beat Nektar Therapeutics's return on equity of -201.73%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    NKTR
    Nektar Therapeutics
    72.66% -$3.60 $13.7M
  • What do Analysts Say About XNCR or NKTR?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 758.56%. Given that Nektar Therapeutics has higher upside potential than Xencor, analysts believe Nektar Therapeutics is more attractive than Xencor.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    NKTR
    Nektar Therapeutics
    4 1 0
  • Is XNCR or NKTR More Risky?

    Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.552, suggesting its less volatile than the S&P 500 by 44.806%.

  • Which is a Better Dividend Stock XNCR or NKTR?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or NKTR?

    Xencor quarterly revenues are $32.7M, which are larger than Nektar Therapeutics quarterly revenues of $10.5M. Xencor's net income of -$48.4M is higher than Nektar Therapeutics's net income of -$50.9M. Notably, Xencor's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 1.38x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.92x -- $32.7M -$48.4M
    NKTR
    Nektar Therapeutics
    1.38x -- $10.5M -$50.9M
  • Which has Higher Returns XNCR or RARE?

    Ultragenyx Pharmaceutical has a net margin of -147.92% compared to Xencor's net margin of -108.46%. Xencor's return on equity of -32.34% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    RARE
    Ultragenyx Pharmaceutical
    79.42% -$1.57 $151.2M
  • What do Analysts Say About XNCR or RARE?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $89.84 which suggests that it could grow by 139.64%. Given that Xencor has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Xencor is more attractive than Ultragenyx Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    RARE
    Ultragenyx Pharmaceutical
    13 1 0
  • Is XNCR or RARE More Risky?

    Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.250, suggesting its less volatile than the S&P 500 by 75%.

  • Which is a Better Dividend Stock XNCR or RARE?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or RARE?

    Xencor quarterly revenues are $32.7M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Xencor's net income of -$48.4M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Xencor's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 5.94x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.92x -- $32.7M -$48.4M
    RARE
    Ultragenyx Pharmaceutical
    5.94x -- $139.3M -$151.1M
  • Which has Higher Returns XNCR or REGN?

    Regeneron Pharmaceuticals has a net margin of -147.92% compared to Xencor's net margin of 26.7%. Xencor's return on equity of -32.34% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    REGN
    Regeneron Pharmaceuticals
    84.67% $7.27 $31.4B
  • What do Analysts Say About XNCR or REGN?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 37.41%. Given that Xencor has higher upside potential than Regeneron Pharmaceuticals, analysts believe Xencor is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    REGN
    Regeneron Pharmaceuticals
    14 6 0
  • Is XNCR or REGN More Risky?

    Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

  • Which is a Better Dividend Stock XNCR or REGN?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.33% to investors and pays a quarterly dividend of $0.88 per share. Xencor pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or REGN?

    Xencor quarterly revenues are $32.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Xencor's net income of -$48.4M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Xencor's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 4.29x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.92x -- $32.7M -$48.4M
    REGN
    Regeneron Pharmaceuticals
    4.29x 13.47x $3B $808.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Is TTD The Big Winner If Pharma Ads Are Banned?
Is TTD The Big Winner If Pharma Ads Are Banned?

Last week, Senators Bernie Sanders and Angus King introduced a…

Is Palantir Stock Overvalued?
Is Palantir Stock Overvalued?

By every traditional yardstick, including a price‑to‑sales well above 100,…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 16

VEON [VEON] is up 2.94% over the past day.

Buy
74
DAVE alert for Jun 16

Dave [DAVE] is up 3.48% over the past day.

Buy
54
DAR alert for Jun 16

Darling Ingredients [DAR] is up 7.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock